The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
News Release
Velocys plc
("the Company")
11th August 2020
Mailing of 2019 annual report and AGM notice
Velocys plc (VLS.L), the sustainable fuels technology company, is pleased to announce that copies of the 2019 annual report and accounts, together with the notice of Annual General Meeting, have been sent to all registered shareholders and will shortly be available for viewing on the Company's website, www.velocys.com.
Annual General Meeting
The Annual General Meeting will be held at 10.45 am on Wednesday 2 September 2020 at the registered office of Velocys plc, Magdalen Centre Robert Robinson Avenue, The Oxford Science Park Oxford OX4 4GA.
In line with the UK Government's Stay Alert Guidance, the Annual General Meeting is expected to be held in a format different to that of previous meetings, while still allowing for Shareholders to exercise their voting rights. It is currently intended that the Annual General Meeting will be held with only the minimum number of Shareholders or proxies present as required to form a quorum under the Company's articles of association, and who are essential for the business of the Annual General Meeting to be conducted. The attendance of any additional Shareholder, proxy or corporate representative is not permitted under the Stay Alert Guidance. Full information is set out the notice of Annual General Meeting.
("Hemogenyx Pharmaceuticals" or the "Company")
CAR-T Agreement with University of Pennsylvania
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has entered into a Sponsored Research Agreement ("Agreement") with the University of Pennsylvania ("Penn"). The goal of the Agreement is to advance the Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") developed by the Company toward clinical trials. The Agreement is envisaged as the first step of a larger program that aims to achieve clinical proof of concept for HEMO-CAR-T for the treatment of acute myeloid leukemia ("AML").
Dr. Saar Gill, Assistant Professor of Medicine, a hematologist-oncologist physician scientist and Scientific co-Director of the Cell Therapy and Transplantation program at Penn, will serve as Principal Investigator on behalf of Penn. Dr. Gill's laboratory is part of the Center for Cellular Immunotherapies ("CCI"), whose Director, Dr. Carl H. June, conducted pioneering clinical trials of genetically engineered cells including CAR-T cells in patients with HIV and diverse forms of cancer.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "This is a first and incredibly important step on a direct path to clinical trials for one of our leading product candidates. We are very pleased to be collaborating with the best and first institution that developed CAR-T technology into an approved and globally used treatment for leukemias, which has already saved so many lives. We are confident that this collaboration will dramatically accelerate the development of our CAR-T product candidate, which we believe will have a significant and positive impact in the treatment of acute myeloid leukemia, for which there is currently no real effective treatment."
About AML and CAR-T Therapy
AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of the new therapy for AML would have a major impact on treatment and survival rates for the disease.
CAR-T therapy is a treatment in which a patient's own T-cells, a type of immune cell, are modified to recognize and kill the patient's cancer cells. The procedure involves: isolating T-cells from the patient; modifying the isolated T-cells in a laboratory using a CAR gene construct (which allows the cells to recognize the patient's cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.
("Eurasia" or "the Company")
Tipil License
Eurasia Mining plc, the palladium, platinum, rhodium, iridium and gold producing company, operating the established West Kytlim Mine in the Urals, and also the operator of the Monchetundra Project comprising two predominantly palladium open pit deposits, located 3km away from Severonickel, one of Norilsk Nickel's largest base metals and PGM processing facilities, near the town of Monchegorsk on the Kola Peninsula, is pleased to announce that the Company has been granted the Tipil exploration license (24.5km2) adjacent and to the west of the current mining permit at West Kytlim.
The Tipil license (24.5km2) contains approximately 17 kilometres of river course and sedimentary units proven to host PGM deposits at the West Kytlim project. Geological data and historical mining information has been analysed by the Company's geologists and a report compiled which justified the application as a new exploration license tenement.
More information about the Tipil license has been provided in the announcements dated 9 April 2020, 4 December 2019 and 17 June 2019.
Comments
Christian Schaffalitzky, Executive Chairman commented: "The Directors are pleased with the permitting progress achieved across all of our projects. Further announcements will be made as appropriate".
HI CHESH . . GOT DISTRACTED TODAY AS I GOT AN INTEREST IN EUA . WHEN IT GOES TO £1 WHICH IT WILL I WILL BE £70 GRAND BETTER OFF . .. YIP THINGS LOOKING GOOD HERE AT MO .